Analysts have been eager to weigh in on the Healthcare sector with new ratings on Penumbra (PEN – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Insulet (PODD – Research Report).
Penumbra (PEN)
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Penumbra, with a price target of $264.00. The company’s shares closed last Thursday at $262.68.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
Currently, the analyst consensus on Penumbra is a Strong Buy with an average price target of $285.13, which is a 11.0% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $289.00 price target.
See the top stocks recommended by analysts >>
BioMarin Pharmaceutical (BMRN)
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical yesterday and set a price target of $100.00. The company’s shares closed last Thursday at $89.97.
According to TipRanks.com, Issi ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $106.35 average price target, which is a 19.1% upside from current levels. In a report released today, Citi also maintained a Hold rating on the stock with a $94.00 price target.
Insulet (PODD)
In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on Insulet, with a price target of $270.00. The company’s shares closed last Thursday at $197.14.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
Insulet has an analyst consensus of Moderate Buy, with a price target consensus of $238.55, implying a 23.6% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $240.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PEN:
